LLM BSc - Purple Biotech Vice Operations

PPBT Stock

USD 2.80 0.07 2.56%

Executive

LLM BSc is Vice Operations of Purple Biotech

Age	53
Phone	972 3 933 3121
Web	https://purple-biotech.com

Purple Biotech Management Efficiency

The company has return on total asset (ROA) of (0.166) % which means that it has lost $0.166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2166) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Purple Biotech to Peers

Predict price of Purple Biotech

Purple Biotech currently holds 4.13 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 6.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Purple Biotech's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	Patricia Hirano	Soleno Therapeutics	58
	PharmD MBA	Soleno Therapeutics	N/A
	Anthony Price	Bio Path Holdings	N/A
	Thomas Dalton	Cingulate	N/A
	Crystal Zuckerman	Pmv Pharmaceuticals	N/A
	Anthony MBA	Bio Path Holdings	N/A
	Raul MD	Cingulate	67
	Robert JD	Pmv Pharmaceuticals	63
	Orly Amiran	Pluri Inc	N/A
	Jeffrey Cole	Cadrenal Therapeutics, Common	N/A
	Veronique AmorBaroukh	Enlivex Therapeutics	N/A
	Patricia MPH	Soleno Therapeutics	59
	Michael Carulli	Pmv Pharmaceuticals	51
	Tim Smith	Pmv Pharmaceuticals	N/A
	Daniel George	Anebulo Pharmaceuticals	55
	Marc MD	Pmv Pharmaceuticals	N/A
	Adam Esq	BioLineRx	N/A
	MD FACC	Cadrenal Therapeutics, Common	70
	Jeff Cole	Cadrenal Therapeutics, Common	N/A
	Matthew MD	Cingulate	61
	Kristen MS	Soleno Therapeutics	56

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Purple Biotech (PPBT) is traded on NASDAQ Exchange in USA. It is located in 4 Oppenheimer Street, Rehovot, Israel, 7670104 and employs 6 people. Purple Biotech is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.22
	Return On Asset	-0.17

Purple Biotech Leadership Team

Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.

	MA CPA, Chief Officer
	Fabien Sebille, Chief Officer
	Michael Schickler, Head Affairs
	LLM BSc, Vice Operations
	Ido Morpurgo, VP Operations
	Nir Livneh, VP Affairs

Purple Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.22
	Return On Asset	-0.17
	Current Valuation	(973.48 K)
	Shares Outstanding	2.65 M
	Shares Owned By Insiders	1.98 %
	Shares Owned By Institutions	3.03 %
	Number Of Shares Shorted	53.98 K
	Price To Book	0.22 X
	Price To Sales	58.08 X
	Gross Profit	(196 K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC